Tag: EnsoData
In brief: EnsoData’s investment, pilot’s fraud algorithm, Kennedy’s infusion stance
June 27, 2025HME News Staff
MADISON, Wis. – EnsoData has received $20 million in Series B financing led by Questa Capital to accelerate adoption of its AI-powered sleep medicine solutions.
“Traditional approaches in sleep medicine have left nearly 80% of patients undiagnosed and, of the 20% that are positively diagnosed, only one in two will be successfully treated,” said Justin Mortara, Ph.D., president and CEO of EnsoData. “We need to expand patient access with simpler and more economic testing...
EnsoData raises $20M
June 25, 2025HME News Staff
MADISON, Wis. – EnsoData has received $20 million in Series B financing led by Questa Capital to accelerate adoption of its AI-powered sleep medicine solutions.
“Traditional approaches in sleep medicine have left nearly 80% of patients undiagnosed and, of the 20% that are positively diagnosed, only one in two will be successfully treated,” said Justin Mortara, Ph.D., president and CEO of EnsoData. “We need to expand patient access with simpler and more economic testing...
EnsoData names new chief commercial officer
May 22, 2025HME News Staff
MADISON, Wis. – EnsoData has named Bobby Cockrill as chief commercial officer to oversee strategy and execution of sales and marketing functions and continue accelerating EnsoSleep PPG, EnsoSleep, RPM and EnsoTherapy adoption across North America. Previously, Cockrill worked at Bardy Diagnostics (BDx), which offered a patch-based cardiac monitoring solution. There, he grew a lean sales team into a force of 60-plus, leading to 100x revenue growth over his eight years. “Bobby’s extensive...
EnsoData adds position data to sleep test
May 20, 2025HME News Staff
MADISON, Wis. – The FDA-cleared EnsoSleep PPG home sleep test now features position data captured by Advanced Brain Monitoring’s Night Shift sleep positioner. Incorporating positional data provides a more complete diagnostic picture of the patient’s sleep: 21% of sleep apnea patients would have little-to-no breathing problems if back-sleeping were avoided, and 70% of patients diagnosed with OSA are substantially more severe when back-sleeping, according to ABM research. “The...
EnsoData releases AI-driven RPM
May 5, 2025HME News Staff
MADISON, Wis. – EnsoData has added a new remote physiological monitoring (RPM) offering to the EnsoSleep PPG ecosystem of AI tools. The RPM solution allows clinicians to seamlessly monitor patients over time and proactively intervene when patients need support with their therapy the most. “The natural evolution for sleep care is in remote physiological monitoring from the home,” said Sam Rush, co-founder and chief AI officer for the company. “Until now, sleep medicine lacked...
Blackstone Medical, EnsoData partner on home sleep testing
April 17, 2025HME News Staff
MADISON, Wis. – Blackstone Medical Services (BMS), a Medicare-approved, JCAHO-accredited and nationally recognized IDTF for home sleep testing, has partnered with EnsoData, an innovator in AI healthtech solutions, to offer improved accessibility to diagnosis and treatment for the millions of patients currently living with undiagnosed sleep apnea. BMS leverages EnsoData’s FDA-cleared, EnsoSleep PPG home sleep testing solution to equip primary care physicians with an effective and efficient...
EnsoData enhances home sleep apnea test
April 14, 2025HME News Staff
MADISON, Wis. – EnsoData is enhancing the EnsoSleep PPG, a home sleep apnea testing solution that’s cleared by the U.S. Food and Drug Administration, by integrating three new physical channels. The company says the new channels will provide additional physiological data to support sleep clinicians in diagnosing and treating sleep disorders using FDA-cleared pulse oximeters. “Adding three new channels is a major step forward for EnsoSleep PPG,” said Fred Turkington, SVP of...
Dr. Watson: It pays to help patients take that final step
March 21, 2025Theresa Flaherty, Managing Editor
MADISON, Wis. – When patients receive an obstructive sleep apnea diagnosis but don’t initiate successful PAP therapy, that creates an opportunity cost across the health care continuum, says Nathaniel Watson, MD, chief medical officer at EnsoData.
“Once somebody's gotten all the way to that point, it's actually really important to get them to be adherent to their treatment,” he said. “To lose out on that last little step is problematic because of all...
Study: PAP adherence saves money
January 29, 2025HME News Staff
BALTIMORE, Md. – Medicare beneficiaries with common chronic health conditions who complied with PAP therapy saw reduced costs, according to a new study. The study, led by Emerson M. Wickwire, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, along with researchers from EnsoData and Santa Barbara Actuaries, found 45% of beneficiaries in the sample were adherent to PAP, 10% were non-adherent, and 44% did not...
BodiMetrics, EnsoData partner
December 3, 2024HME News Staff
MADISON, Wis. - BodiMetrics, which makes well-being and fitness monitoring devices, has announced a partnership that will power its FDA-cleared circul pro smart ring with EnsoData’s EnsoSleep PPG software to increase affordability and accessibility of home sleep apnea testing and longitudinal sleep monitoring. The accuracy, comfort and flexibility of the circul pro ring, coupled with EnsoSleep PPG software, provides clinicians across the medical spectrum with an anytime, anywhere sleep diagnostic...